由于肾功能的加速下降，糖尿病对后续的肾性贫血是一种风险，全球糖尿病患者总人数继续指数增长。在临床研究中，作为治疗糖尿病的药物之一，钠-葡萄糖共转运体2（SGLT2）抑制剂最近引起了对其作为抗贫血药物的关注，但对此仍缺乏证据。本研究旨在通过利用血红蛋白（Hb）水平作为指标，调查SGLT2抑制剂治疗对贫血抑制的效果。我们进行了一项纵向研究，评估并比较接受SGLT2抑制剂治疗的糖尿病患者（n=48）和接受DPP-4抑制剂治疗的糖尿病患者（n=48）的Hb水平的变化。研究参与者根据性别分层，并观察参与者90天的Hb水平轨迹。我们评估了SGLT2抑制剂作为防止Hb水平下降的预防因子，并将其与DPP-4抑制剂进行了比较[奥斯比（OR）=3.40，95%置信区间（CI）=1.93-6.00]。男性Hb水平的基线至90天时，SGLT2抑制剂和DPP-4抑制剂的使用导致14.4±0.34和12.4±0.31 g/dl的下降（p<0.001）。值得注意的是，SGLT2抑制剂对Hb水平下降的预防效果与肾功能和性别无关。SGLT2抑制剂能够防止Hb水平下降，并显示出抗贫血效应。版权所有 © 2023年，国际抗癌研究学会（Dr. George J. Delinasios），保留所有权利。

Diabetes mellitus is a risk for subsequent nephrogenic anemia due to accelerated decline in renal function, and the global diabetic population continues to grow exponentially. In clinical studies, sodium-glucose co-transporter 2 (SGLT2) inhibitors, one of the drugs used to treat diabetes, have recently attracted attention as anemia suppressors, but there is still lack of evidence on this matter. The present study aimed to investigate the effects of SGLT2 inhibitor administration on anemia suppression using hemoglobin (Hb) levels as an indicator.We conducted a longitudinal study to evaluate and compare the changes in Hb levels in diabetes patients treated with SGLT2 inhibitors (n=48) and those treated with DPP-4 inhibitors (n=48). Study participants were stratified into sub-cohorts based on sex, and the Hb level trajectory in the participants was observed for 90 days.We evaluated the use of SGLT2 inhibitors as a prophylactic factor for the decline in Hb levels and compared it to that of DPP-4 inhibitors [odds ratio (OR)=3.40, 95% confidence interval (CI)=1.93-6.00]. Administration of SGLT2 inhibitors and DPP-4 inhibitors resulted in decline of 14.4±0.34 and 12.4±0.31 g/dl (p<0.001), respectively, in male Hb levels from baseline to 90 days. Notably, the prophylactic effect of SGLT2 inhibitors on the reduction in Hb levels was independent of renal function and sex.SGLT2 inhibitors prevent the reduction in Hb levels and exhibit anti-anemic effects.Copyright © 2023, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.